Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 62.5%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
Low

Intervention not reported

Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1956 participants
Very low

Intervention not reported

Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Very low

Intervention not reported

Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Very low

Intervention not reported

Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Low

Intervention not reported

Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Low